ARALAST & Viral Safety

• Should Your Patient Be Tested
• Your Newly Diagnosed Patient
• Managing Your AAT Deficient Patient

ARALAST is manufactured for Baxter, a leader in the field of plasma processing. The processing of ARALAST is designed to help reduce the risk of viral transmission with two key steps. ARALAST is the only A₁-PI therapy that utilizes both:

• Solvent/detergent – inactivates lipid-enveloped viruses (eg, HIV, HBV, HCV)
• Nanofiltration – reduces the risk of transmission of nonlipid-enveloped viruses (eg, HAV, parvovirus B19)

*Viruses (numbers shown in table) were deliberately added and eliminated.
†HIV-1: Fractionation units log₁₀, SFU SD treatment units log₁₀, TCID₅₀/mL
‡BVD (bovine viral diarrhea), PRV (Pseudorabies virus): SD treatment unit log₁₀, PFU/mL, nanofiltration units log₁₀, PFU
§HAV (hepatitis A), PPV (porcine parvovirus), nanofiltration units log₁₀, PFU
•Not applicable

As with all plasma-derived therapeutics, the potential to transmit infectious agents cannot be totally eliminated.

ARALAST [Alpha₁-Proteinase Inhibitor (Human)] is indicated for chronic augmentation therapy in patients having congenital deficiency of A₁-PI with clinically evident emphysema. ARALAST is not indicated as therapy for lung disease patients in whom congenital A₁-PI deficiency has not been established.

Please review the Important Safety Information and the Full Prescribing Information